<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Basic Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Basic Med Sci</journal-id><journal-id journal-id-type="publisher-id">IJBMS</journal-id><journal-title-group><journal-title>Iranian Journal of Basic Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">2008-3866</issn><issn pub-type="epub">2008-3874</issn><publisher><publisher-name>Mashhad University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">IJBMS-17-497</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>p63 is more sensitive and specific than 34&#x003b2;E12 to differentiate adenocarcinoma of prostate from cancer mimickers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kalantari</surname><given-names>Mahmoud Reza</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Anvari</surname><given-names>Kazem</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jabbari</surname><given-names>Hasan</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tabrizi</surname><given-names>Fatemeh Varshoee</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1 </label> Kidney Transplantation Complications Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
</aff><aff id="aff2"><label>2 </label> Solid Tumor Treatment Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
</aff><aff id="aff3"><label>3 </label> Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
</aff><author-notes><corresp id="cor1"><label>*</label><italic>Corresponding author:</italic> Fatemeh Varshoee Tabrizi. Solid Tumor Treatment Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. email: <email>varshoeef1@mums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2014</year></pub-date><volume>17</volume><issue>7</issue><fpage>497</fpage><lpage>501</lpage><history><date date-type="received"><day>6</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>6</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Iranian Journal of Basic Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective(s):</title><p>Prostate cancer is the world's leading cause of cancer and the second cause of cancer-related death in men after lung cancer. Differentiation of prostate adenocarcinoma from benign prostate lesions and hyperplasia sometimes cannot be done on the basis of morphologic findings. Considering the fact that in the prostate adenocarcinoma there is no basal cell layer, basal cell markers can help to differentiate prostate adenocarcinoma from cancer mimickers.</p></sec><sec><title>Materials and Methods:</title><p>We studied 98 prostate biopsy blocks (40 adenocarcinoma and 58 benign lesions) for basal cell marker expression.</p></sec><sec><title>Results:</title><p>p63 and 34&#x003b2;E12 were negative in all prostate adenocarcinoma specimens, but all benign prostate hyperplasia and high grade intraepithelial neoplasia cases expressed them.</p></sec><sec><title>Conclusion:</title><p>Basal cell markers can help to distinguish prostate adenocarcinoma from cancer mimickers.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Basal cell markers</kwd><kwd>Cancer mimickers</kwd><kwd>Prostate adenocarcinoma</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Prostate cancer is the world&#x02019;s leading cause of cancer and the second cause of cancer-related death in men after lung cancer. Cancer of the prostate is typically a disease of men over age 50 (<xref rid="R1" ref-type="bibr">1</xref>). The age adjusted incidence of prostate cancer in the United States is 69 per 100,000. The incidence of latent prostate cancer is even higher. It increases from 20% in men in their fifties to approximately 70% in men between the ages of 70 and 80.</p><p>Differentiation of prostate adenocarcinoma from benign prostate lesions and hyperplasia sometimes cannot be done on the sole basis of morphologic findings; In these cases the diagnosis can be made according to the presence or absence of the basal cell layer, considering the fact that in the prostate adenocarcinoma there is no basal cell layer but benign lesion encirclement by this layer. Hence, using basal cell immunohistochemistry markers including p63 and 34&#x003b2;E12 seems useful in distinguishing these two important categories of prostate lesions.</p><p>On the other hand, studies have shown that some adenocarcinomas show basal cell layer at least partially by p63 and 34&#x003b2;E12 staining.</p><p>As a few cases of adenocarcinoma mimickers and benign prostatic hyperplasia (BPH) don&#x02019;t express basal cell markers, we decided to determine and compare the sensitivity and specificity of these two markers to distinguish adenocarcinoma of prostate from its mimickers.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>In this cross sectional study we had 98 prostate specimens in the Pathology Department, Ghaem Hospital, Mashhad, Iran that were referred for pathologic assessment. These specimens were collected between April 2009 and March 2010. Out of 98 cases; 40 cases were prostate adenocarcinomas and 58 were benign diseases (cancer mimickers) (Table <xref ref-type="table" rid="T1">1</xref>).</p><p>Sampling procedures were different, including transurethral resection (TUR), needle biopsy and prostate adenectomy.</p><p>Biopsy specimens were fixed in 10% formalin. We reviewed the microscopic slides; confirmed Gleason score and grade in prostatic adenocarci-noma cases; and provided 4 &#x003bc;m slices from paraffin blocks. Immunohistochemical staining was performed for basal cell markers, including high molecular
weight cytokeratin (HMWCK) and p63 (DAKO
company).</p><p>p63 antibody (Ab) was diluted to 1/100
concentration and 34&#x003b2;E12 Ab was ready to use.</p><p>We used two-step polymer method (Envision) for
staining the slides. 34&#x003b2;E12 cytoplasmic stain and
p63 nuclear stain were accepted as positive. We
divided basal cell staining into three categories; &#x0003c;5%,
5&#x02013;75%, and &#x0003e;75% (<xref rid="R2" ref-type="bibr">2</xref>).</p><sec><title>Statistical analysis</title><p>Chi-square and Fisher&#x02019;s exact tests were used to
compare the p63 and 34BE12 percentage and
staining intensity data.</p></sec></sec><sec sec-type="results"><title>Results</title><p>All BPH cases were immunoreactive for p63 in
more than 75% of the basal cells (sensitivity 100%) (Figure <xref ref-type="fig" rid="F1">1</xref>). Two out of 40 cases of prostate adenocarcinoma
were excluded because of small limited foci.
The remaining 38 cases had shown no p63
immunoreactivity (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><p>All cases with high grade prostatic intraepithelial
neoplasia (HGPIN) were immunoreactive for p63 in more than 75% of the cells. 8 out of 12 cases of
adenosis had 5&#x02013;75% p63 immunoreactivity. It was
less than 5% in the remaining 4 cases.</p><p>In 16 cases with partial atrophia, 6 cases showed
p63 reactivity in 5&#x02013;75% of the cells and 10 cases
were reactive in less than 5% (Table <xref ref-type="table" rid="T2">2</xref>).</p><p>In all BPH cases, basal cells showed immunoreactivity for 34&#x003b2;E12 in &#x0003e; 75% (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><p>Two out of 40 cases of adenocarcinoma were
excluded because of small limited foci; the remaining
38 cases were 34&#x003b2;E12 negative.</p><p>All 10 cases of HGPIN were immunoreactive for
34&#x003b2;E12 in &#x0003e;75%. 6 out of 12 cases of adenosis
showed reactivity in 5&#x02013;75% of their cells, 2 cases
showed reactivity in &#x0003c;5%, and 2 cases did not show
34&#x003b2;E12 reactivity.</p><p>Four out of 16 partial atrophy cases had 5&#x02013;75%
reactive cells, while 6 cases were reactive in &#x0003c;5%
(partially staining) and 6 cases were negative for
34&#x003b2;E12 immunoreactivity (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>In 8 cases of BPH , 8 cases of adenocarcinoma,
two cases of HGPIN , 4 cases of adenosis, and 8 cases
of partial atrophy , the epithelial cell cytoplasms
showed non-specific staining for 34&#x003b2;E12 with weak
to moderate intensity (Figures <xref ref-type="fig" rid="F3">3</xref>&#x02013;<xref ref-type="fig" rid="F5">5</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In 1984, Gown and Vogel reported for the first
time that high molecular weight (HMW) anti keratin
Ab stained prostatic basal cells specifically (<xref rid="R3" ref-type="bibr">3</xref>).
Results of later studies showed that basal cells exist
only in normal prostatic gland but not in prostatic
adenocarcinoma (<xref rid="R4" ref-type="bibr">4</xref>&#x02013;<xref rid="R6" ref-type="bibr">6</xref>). Wojno and Epstein showed
that in highly suspicious for prostate cancer cases,
the proof of basal cell absence by 34&#x003b2;E12 marker is
very helpful to confirm prostate adenocarcinoma
diagnosis (<xref rid="R7" ref-type="bibr">7</xref>).</p><p>Signoretti <italic>et al</italic> reported that all basal cells
express p63, therefore, this marker can be useful in
distinguishing benign lesions from prostate
malignancy (<xref rid="R8" ref-type="bibr">8</xref>). Person <italic>et al</italic> showed that p63
isexpressed in normal basal cells and benign prostate
hyperplasia (BPH). It is focally expressed in prostate
atrophy and HGPIN, but there is no p63 expression in
the majority of prostate adenocarcinomas (<xref rid="R9" ref-type="bibr">9</xref>).
However, some studies showed p63 and 34&#x003b2;E12 negativity in some benign lesions such as adenosis,
prostate atrophy, and HGPIN (<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R10" ref-type="bibr">10</xref>&#x02013;<xref rid="R15" ref-type="bibr">15</xref>).</p><p>In this study, IHC staining for 34&#x003b2;E12 was
negative in 4 cases with adenosis and 6 cases with
partial atrophy, but they showed patchy positivity
for p63. There are different reasons for unexpressed
34&#x003b2;E12, such as unexpressed 34&#x003b2;E12 gene, formalin
fixation interval, and long term fixation which may
result in 34&#x003b2;E12 Ag deficiency (<xref rid="R16" ref-type="bibr">16</xref>).</p><p>IHC techniques, especially Ag retrieval method
has a role in 34&#x003b2;E12 expression detection (<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>),
but staining differences were more specific in transurethral
prostate biopsy (TURP) (<xref rid="R18" ref-type="bibr">18</xref>).</p><p>Multhaupt <italic>et al</italic> reported that 88% of benign
glands in the transitional zone lost 34BE12 antigenicity
without Ag retrieval, in TURP samples (<xref rid="R19" ref-type="bibr">19</xref>).</p><p>In this study like others, adenocarcinoma were
p63 and 34&#x003b2;E12 (basal cell markers) negative, while
benign lesions expressed them in more than 75%. In
some studies basal cell markers were focally positive
in morphologically benign lesions such as BPH
(<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R18" ref-type="bibr">18</xref>).</p><p>In this study, specificity and sensitivity of p63 and
34&#x003b2;E12 were 100% in pure benign lesions and
adenocarcinoma.</p><p>Our results showed p63 expression in 36 cancer
mimicker cases; however, in some, p63 expressed
patchy positivity. In some studies cancer mimickers,
such as partial atrophy and adenosis, expressed p63
focally, which supports our findings (<xref rid="R2" ref-type="bibr">2</xref>).</p><p>In the Wang <italic>et al</italic> study, 30% of partial atrophy
cases were p63 and 34&#x003b2;E12 negative (cancer
pattern)(<xref rid="R2" ref-type="bibr">2</xref>).</p><p>On the other hand, there are studies showing that
p63 expression in some adenocarcinoma cases may
be due to trapped benign glands between malignant
cells (<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R24" ref-type="bibr">24</xref>).</p><p>In the Shah <italic>et al</italic> study, 2 out of 27 partial atrophy
cases were 34&#x003b2;E12 negative, but p63 was positive
(<xref rid="R18" ref-type="bibr">18</xref>). In our study 10 out of 28 cases of cancer
mimickers (25%) were 34&#x003b2;E12 negative but all
(100%) were p63 positive. It seems that p63 is more
specific than 34&#x003b2;E12 to distinguish prostate cancer
mimickers from adenocarcinoma, which is clinically
important.</p><p>There was a problem in 34&#x003b2;E12 staining, like in
the Shah study (<xref rid="R18" ref-type="bibr">18</xref>). This problem was nonspecific
epithelial cell staining in 8 (25%) BPH (Figure <xref ref-type="fig" rid="F3">3</xref>), 8
(21%) adenocarcinoma (Figure <xref ref-type="fig" rid="F4">4</xref>), and 14 (35%) cancer mimicker cases, which complicates diagnosis.</p><p>Other IHC markers, which preferentially are
overexpressed in prostate cancer cells but not
in basal cells, are &#x003b1;-methyl-acyl-co A (AMACR) (<xref rid="R25" ref-type="bibr">25</xref>&#x02013;<xref rid="R28" ref-type="bibr">28</xref>) and recently introduced marker
erythroblastosisvirus E26 oncogene (ERG), which
can improve distinguishing benign epithelial lesions
from prostate adenocarcinoma (<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R29" ref-type="bibr">29</xref>&#x02013;<xref rid="R31" ref-type="bibr">31</xref>).</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>Other than selection bias in sampling, the
specificity and sensitivity of p63 and 34&#x003b2;E12 in true
adenocarcinoma and benign lesions (BPH) are high,
but in cancer mimickers, especially, when
morphologic differentiation is impossible between
benign and malignant lesions, p63 sensitivity is
significantly higher than 34&#x003b2;E12.</p><p>Moreover, 34&#x003b2;E12 nonspecific staining in benign
lesions is a problem in interpretation of the results;
therefore, in our opinion, p63 is a better marker than
34&#x003b2;E12 for differentiation of benign lesions from
prostate adenocarcinoma.</p><p>In clinical practice, combination of prostate
cancer and basal cell markers is helpful for improved
differentiation of prostate cancers from mimickers.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors would like to thank the Deputy of
Research, Mashhad University of Medical Sciences,
Mashhad, Iran for supporting this study.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="book" publisher-type="book"><person-group person-group-type="author"><name><surname>Rosai</surname><given-names>J</given-names></name></person-group><source>Rosai and Ackermans surgical pathology</source><year>2012</year><edition>11th</edition><publisher-loc>Edinburg</publisher-loc><publisher-name>Mosby</publisher-name><fpage>1295</fpage></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name></person-group><article-title>Parthial atrophy on prostate needle biopsy cores: a morphologic and immune histochemical study</article-title><source>AM J Surg Pathol</source><year>2008</year><volume>32</volume><fpage>851</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">18408595</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gown</surname><given-names>AM</given-names></name><name><surname>Vogel</surname><given-names>AM</given-names></name></person-group><article-title>Monoclonal antibodies to human intermediate filament proteins: II. Distribution of filament proteins in normal human tissues</article-title><source>Am J Pathol</source><year>1984</year><volume>114</volume><fpage>309</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">6320650</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Brawer</surname><given-names>MK</given-names></name><name><surname>Peehl</surname><given-names>DM</given-names></name><name><surname>Stamy</surname><given-names>TA</given-names></name><name><surname>Bostwick</surname><given-names>DG</given-names></name></person-group><article-title>keratin immune reactivity in the being and neoplastic human prostate</article-title><source>Cancer Res</source><year>1985</year><volume>45</volume><fpage>3663</fpage><lpage>3667</lpage><pub-id pub-id-type="pmid">2410099</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hedrick</surname><given-names>L</given-names></name><name><surname>Epstien</surname><given-names>JI</given-names></name></person-group><article-title>Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma</article-title><source>Am J Surg Pathol</source><year>1983</year><volume>13</volume><fpage>350</fpage><lpage>353</lpage></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>O'Malley</surname><given-names>FP</given-names></name><name><surname>Grignon</surname><given-names>DJ</given-names></name><name><surname>shum</surname><given-names>DT</given-names></name></person-group><article-title>Use fullness of immune peroxides staining with high &#x02013; molecular &#x02013; weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland</article-title><source>Virchows Arch A Patathol Anat Histopathol</source><year>1995</year><volume>417</volume><fpage>191</fpage><lpage>196</lpage></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wogno</surname><given-names>KJ</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name></person-group><article-title>The utility of basal cell-specific anti cyto keratin antibody (34 beta E 12) in the diagnosis of prostate cancer: a review of 228 cases</article-title><source>Am J Surg Pathol</source><year>1995</year><volume>19</volume><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">7532918</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Waltregny</surname><given-names>D</given-names></name><name><surname>Dilks</surname><given-names>J</given-names></name><name><surname>Isaac</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Garraway</surname><given-names>L</given-names></name><etal/></person-group><article-title>P63 is a prostate basal cell marker and is required for prostate development</article-title><source>Am J Pathol</source><year>2000</year><volume>157</volume><fpage>1769</fpage><lpage>1775</lpage><pub-id pub-id-type="pmid">11106548</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>GK</given-names></name><name><surname>Gage</surname><given-names>WR</given-names></name><name><surname>Nelson</surname><given-names>WG</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name></person-group><article-title>P63 protein expression is rare in prostate adenocarcinoma:implications for cancer diagnosis and carcinogenesis</article-title><source>Urology</source><year>2001</year><volume>58</volume><fpage>619</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">11597556</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>MB</given-names></name><name><surname>Tamboli</surname><given-names>P</given-names></name><name><surname>Varma</surname><given-names>M</given-names></name><name><surname>Srigley</surname><given-names>JR</given-names></name></person-group><article-title>Postatrophic hyper plasia of the prostate gland: e detailed analysis of its morphology in needle biopsy specimens</article-title><source>Am J Surg Pathol</source><year>1999</year><volume>23</volume><fpage>925</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">10435562</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="book" publisher-type="book"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>PA</given-names></name></person-group><source>Prostate pathology</source><year>2003</year><publisher-loc>Chicago</publisher-loc><publisher-name>ASCP press</publisher-name></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Oppenheimer</surname><given-names>JR</given-names></name><name><surname>Wills</surname><given-names>ML</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name></person-group><article-title>Partial atrophy in prostate needle cores: Another diagnostic pitfall for the surgical pathologist</article-title><source>Am J Surg Pathol</source><year>1998</year><volume>22</volume><fpage>440</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">9537471</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name></person-group><article-title>Basal cell cocktail(34 BE12+p63) improve the detection of prostate basal cells</article-title><source>Am J Surg Pathol</source><year>2003</year><volume>27</volume><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">12604893</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gaudin</surname><given-names>PB</given-names></name><name><surname>Epstein</surname><given-names>JJ</given-names></name></person-group><article-title>Adenosis of the prostate. Histologic features in needle biopsy specimens</article-title><source>Am J Surg Pathol</source><year>1995</year><volume>19</volume><fpage>737</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">7793471</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bost</surname><given-names>Wick DG</given-names></name><name><surname>Srigley</surname><given-names>J</given-names></name><name><surname>Grignon</surname><given-names>D</given-names></name><name><surname>Maksem</surname><given-names>J</given-names></name><name><surname>Humphrey</surname><given-names>P</given-names></name><name><surname>van der Kwast</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Atypical adenomatous hyper plasia of the prostate:morphologic criteria for its distinction from well-differetiated carcinoma</article-title><source>Hum Pathol</source><year>1993</year><volume>24</volume><fpage>819</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">8375853</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>M</given-names></name><name><surname>Linden</surname><given-names>MD</given-names></name><name><surname>Amin</surname><given-names>MB</given-names></name></person-group><article-title>Effect of formalin fixation and epitope retrieval thechniques on antibody 34betaE12 immunostaining of prostate tissues</article-title><source>Mod Pathol</source><year>1999</year><volume>12</volume><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">10349984</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Jczkowski</surname><given-names>KA</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Craeford</surname><given-names>BG</given-names></name><name><surname>Bostwick</surname><given-names>DG</given-names></name></person-group><article-title>Steam heat with on EDTA boffer and protease digestion optimizes immune histochemical expression of basal cell-specific antikertin 34 beta E12 to discriminate cancer in prostatic epithelium</article-title><source>Mod Pathol</source><year>1999</year><volume>12</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9950154</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>RB</given-names></name><name><surname>Ming</surname><given-names>Z</given-names></name><name><surname>Le Blanc</surname><given-names>M</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name></person-group><article-title>Comparison of the basal cell-specific,markers,34BE12 and P63,in the diagnosis of prostate cancer</article-title><source>Am J Surg Pathol</source><year>2002</year><volume>26</volume><fpage>1161</fpage><lpage>1168</lpage><pub-id pub-id-type="pmid">12218572</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Multhaupt</surname><given-names>HA</given-names></name><name><surname>Fessler</surname><given-names>JN</given-names></name><name><surname>Warol</surname><given-names>MJ</given-names></name></person-group><article-title>Loss of high-molecular weight antigenicity in prostate tissue obtained by trans urethral resection</article-title><source>Arch Pathol Lab Med</source><year>2000</year><volume>124</volume><fpage>1764</fpage><lpage>1770</lpage><pub-id pub-id-type="pmid">11100054</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Leck</surname><given-names>Sell K</given-names></name><name><surname>Gaudin</surname><given-names>P</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name></person-group><article-title>Rare expression of high molecular &#x02013;weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer</article-title><source>Am J Surg Pathol</source><year>1999</year><volume>23</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">9989840</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>IA</given-names></name><name><surname>Schlageter</surname><given-names>MO</given-names></name><name><surname>Stinett</surname><given-names>P</given-names></name><name><surname>Lechago</surname><given-names>J</given-names></name></person-group><article-title>Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate</article-title><source>Mod Pathol</source><year>1991</year><volume>4</volume><fpage>220</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">1710806</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Lindeman</surname><given-names>N</given-names></name><name><surname>Weinder</surname><given-names>N</given-names></name></person-group><article-title>Immuno histochemical profile of prostatic and urothelial carcinoma impact of heat-induced epitope retrieval and presentation of tumors with inter mediate features</article-title><source>Appl Immuno Histochem</source><year>1996</year><volume>4</volume><fpage>264</fpage><lpage>275</lpage></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Oliai</surname><given-names>BR</given-names></name><name><surname>Kahane</surname><given-names>H</given-names></name><name><surname>Epstein</surname><given-names>JJ</given-names></name></person-group><article-title>Can basal cells be seen in adenocarcinoma of the prostate? an immunohistochemical study using high molewlar weight cytokeratin (clone 34BE 12) antibody</article-title><source>Am J Surg Pathol</source><year>2002</year><volume>26</volume><fpage>1151</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">12218571</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Herawi</surname><given-names>M</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name></person-group><article-title>Immunohistochemical anti body cocktail staining (P63/HMWCK/AMACR) of ductal carcinoma and gleason pattern 4 cribiform and non cribiform acinar adenocarcinomas of the prostate</article-title><source>Am J Surg Pathol</source><year>2007</year><volume>31</volume><fpage>889</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">17527076</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Beach</surname><given-names>R</given-names></name><name><surname>Gown</surname><given-names>AM</given-names></name><name><surname>De Peralta-Venturina</surname><given-names>MN</given-names></name></person-group><article-title>P504S immunohistochemical detection in 405 prostatic specimens including 376 18- gauge needle biopsies</article-title><source>Am J Surg Pathol</source><year>2002</year><volume>26</volume><fpage>1588</fpage><lpage>1596</lpage><pub-id pub-id-type="pmid">12459625</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Browne</surname><given-names>TJ</given-names></name><name><surname>Hirsch</surname><given-names>MS</given-names></name><name><surname>Brodsky</surname><given-names>G</given-names></name><name><surname>Welch</surname><given-names>WR</given-names></name><name><surname>Loda</surname><given-names>MF</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name></person-group><article-title>Prospective evaluation of AMACR (P504S) and basal cell markers in the assesssment of routine prostate needle biopsy specimens</article-title><source>Hum Pathol</source><year>2004</year><volume>35</volume><fpage>1462</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">15619204</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Woda</surname><given-names>BA</given-names></name><name><surname>Rock</surname><given-names>KL</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Savas</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><etal/></person-group><article-title>P504S:a new molecular marker for detection of prostate carcinoma</article-title><source>Am J Surg Pathol</source><year>2001</year><volume>25</volume><fpage>1397</fpage><lpage>1404</lpage><pub-id pub-id-type="pmid">11684956</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name><name><surname>Barrette</surname><given-names>TR</given-names></name><name><surname>Sanda</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>1662</fpage><lpage>1670</lpage><pub-id pub-id-type="pmid">11926890</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Furusato</surname><given-names>B</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Dobi</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Mohamed</surname><given-names>AA</given-names></name><etal/></person-group><article-title>ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification</article-title><source>Prostate Cancer Prostatic Dis</source><year>2010</year><volume>13</volume><fpage>228</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">20585344</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Yaskiv</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Simmerman</surname><given-names>K</given-names></name><name><surname>Daly</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Falzarano</surname><given-names>S</given-names></name><etal/></person-group><article-title>The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies</article-title><source>Am J Surg Pathol</source><year>2010</year><volume>35</volume><fpage>1062</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">21623182</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Tomlin</surname><given-names>SA</given-names></name><name><surname>Mudaliar</surname><given-names>KM</given-names></name><name><surname>Chiu</surname><given-names>YL</given-names></name><name><surname>Esgueva</surname><given-names>R</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><etal/></person-group><article-title>Antibody-based detection of ERG rearangement-positive prostate cancer</article-title><source>Neoplasia</source><year>2010</year><volume>12</volume><fpage>590</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">20651988</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p> A benign prostate biopsy (BPH) stained with p63. The basal cells show moderate to severe nuclear staining. Nuclei of epithelial cells are negative for p63 </p></caption><graphic xlink:href="IJBMS-17-497_F1"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p> Prostate adenocarcinoma is negative for p63 immunostaining. There is no non-specific staining in cancer cells </p></caption><graphic xlink:href="IJBMS-17-497_F2"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p> A benign prostate biopsy stained with 34BE12. The basal cells reveal cytoplasmic staining with moderate intensity. The epithelial cells show non-specific cytoplasmic staining with
mild intensity </p></caption><graphic xlink:href="IJBMS-17-497_F3"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p> A prostate biopsy harboring cancer stained with
34BE12. The cancer cells show non-specific cytoplasmic staining
with moderate intensity </p></caption><graphic xlink:href="IJBMS-17-497_F4"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>A benign prostate gland (atrophic gland) stained with
34BE12. Both basal cells and epithelial cells show
immunoreactivity</p></caption><graphic xlink:href="IJBMS-17-497_F5"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Frequency of pathologic lesions in prostate specimens</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Diagnosis</th><th rowspan="1" colspan="1">Number</th></tr><tr><th colspan="2" rowspan="1"><hr/></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">40</td></tr><tr><td rowspan="1" colspan="1">Benign prostatic hyperplasia</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1">High grade prostatic intraepithelial neoplasia</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td rowspan="1" colspan="1">Adenosis</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">Partial atrophy</td><td align="center" rowspan="1" colspan="1">16</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>p63Immunoreactivity in adenocarcinoma of prostate and cancer mimickers</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th rowspan="3" colspan="1">Diagnosis </th><th rowspan="1" colspan="1">Number</th><th colspan="4" rowspan="1">p63 reactivity percentage</th><th rowspan="3" colspan="1">p63 reactivity intensity</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">0%</th><th rowspan="1" colspan="1">&#x0003c;5%</th><th rowspan="1" colspan="1">5-75%</th><th rowspan="1" colspan="1">&#x0003e;75%</th></tr><tr><th colspan="7" rowspan="1"><hr/></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">BPH</td><td align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">+++</td></tr><tr><td rowspan="1" colspan="1">HGPIN</td><td align="center" rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">+++</td></tr><tr><td rowspan="1" colspan="1">Adenosis</td><td align="center" rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">++</td></tr><tr><td rowspan="1" colspan="1">Partial atrophy</td><td align="center" rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">++/+++</td></tr></tbody></table><table-wrap-foot><fn id="T2F1"><p> BPH: Benign prostatic hyperplasia; HGPIN: High grade prostatic intraepithelial neoplasia </p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>34&#x003b2;E12 Immunoreactivity in adenocarcinoma of prostate and cancer mimickers</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th rowspan="3" align="left" colspan="1">Diagnosis </th><th rowspan="3" colspan="1">Number</th><th colspan="4" rowspan="1">34&#x003b2;eta E12 reactivity percentage</th><th rowspan="3" colspan="1">34&#x003b2;eta E12 Reactivity intensity</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1">0%</th><th rowspan="1" colspan="1">&#x0003c;5%</th><th rowspan="1" colspan="1">5-75%</th><th rowspan="1" colspan="1">&#x0003e;75%</th></tr><tr><th colspan="7" rowspan="1"><hr/></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">BPH</td><td align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">+++</td></tr><tr><td rowspan="1" colspan="1">HGPIN</td><td align="center" rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">+++</td></tr><tr><td rowspan="1" colspan="1">Adenosis</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-/++</td></tr><tr><td rowspan="1" colspan="1">Partial atrophy</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-/++</td></tr></tbody></table><table-wrap-foot><fn id="T3F1"><p> BPH: Benign prostatic hyperplasia; HGPIN: High grade prostatic intraepithelial neoplasia</p></fn></table-wrap-foot></table-wrap></floats-group></article>
